Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 15:13:1013641.
doi: 10.3389/fendo.2022.1013641. eCollection 2022.

Effect of levothyroxine replacement therapy in patients with subclinical hypothyroidism and chronic heart failure: A systematic review

Vincenzo Triggiani  1 , Antonio Cittadini  2 , Giuseppe Lisco  1
Affiliations

Effect of levothyroxine replacement therapy in patients with subclinical hypothyroidism and chronic heart failure: A systematic review

Vincenzo Triggiani et al. Front Endocrinol (Lausanne). .

Abstract

Background: Chronic heart failure (CHF) affects the health care system with high social and economic costs due to recurrent hospital admissions or frequent ambulatory reassessments. Subclinical hypothyroidism (SCH) is commonly observed in patients with CHF and negatively affects myocardial function and remodeling and, ultimately, increases the risk of hospitalizations and all-cause and cardiovascular (CV) mortality. The role of levothyroxine replacement on relevant CV outcomes in patients with SCH and CHF is unclear.

Objective: To assess the effect of levothyroxine (compared to placebo or no treatment) on the incidence of all-cause and CV mortality, major adverse CV events, and heart failure in patients with SCH and CHF.

Methods: PubMed/MEDLINE, Cochrane Library, and ClinicalTrial.gov were searched for randomized clinical trials, non-randomized observational, multicentric, and comparative studies. No language restrictions were included. After duplicate removal, articles were screened and extracted for the synthesis according to a hierarchical strategy that included title, abstract, and full-text appraisal. The risk of bias was assessed by RoB2 and ROBIN-I tools. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was applied to rate the quality of evidence and grade the strength of recommendations.

Results: Two trials were included in the systematic review with considerable indirectness and inaccuracy that down-graded the level of evidence.

Discussion: No evidence supports the use of levothyroxine for treating SCH in CHF due to the lack of reliable and well-designed clinical trials.

Conclusion: CV outcome and dose-response trials are needed to understand better the role of levothyroxine replacement treatment for a safer prescription in this clinical setting.

Keywords: all-cause mortality; cardiovascular mortality; chronic heart failure; levothyroxine; subclinical hypothyroidism.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Diagram of selection of included studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. . Universal definition and classification of heart failure: A report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail (2021) 27(4):387–413. doi: 10.1016/j.cardfail.2021.01.022 - DOI - PubMed
    1. Cittadini A, Salzano A, Iacoviello M, Triggiani V, Rengo G, Cacciatore F, et al. . Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: The T.O.S.CA. registry. Eur J Prev Cardiol (2021) 28(15):1691–700. doi: 10.1093/EURJPC/ZWAB020 - DOI - PubMed
    1. Triggiani V, Lisco G. Commentary on the article “Multiple hormonal and metabolic deficiency syndrome predicts outcome in heart failure: The T.O.S.CA. registry”, Antonio cittadini et al. eur. j. prev. cardiol. 2021. Endocr. Metab Immune Disord Drug Targets (2022) 22(6):545–8. doi: 10.2174/1871530321666211215144023 - DOI - PubMed
    1. Arcopinto M, Salzano A, Bossone E, Ferrara F, Bobbio E, Sirico D, et al. . Multiple hormone deficiencies in chronic heart failure. Int J Cardiol (2015) 184(1):421–3. doi: 10.1016/j.ijcard.2015.02.055 - DOI - PubMed
    1. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. . ESC Guidelines for the diagnosis and treatment of acute and chronic heart FailureDeveloped by the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J (2021) 42 (36):3599–726. doi: 10.1093/EURHEARTJ/EHAB368 - DOI - PubMed

Publication types